AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02163824
Drug: KPI-121 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KPI-121 drug product will be supplied as 1.0% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
Trial: NCT02163824
Drug: Vehicle of KPI-121 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control arms will receive the same bottles containing vehicle of KPI-121 including all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
Trial: NCT02163824
Drug: Vehicle of KPI-121 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control arms will receive the same bottles containing vehicle of KPI-121 including all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
Trial: NCT00855465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo tid orally for 16 weeks
Trial: NCT00466440
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose, then po QD until unblinding
Trial: NCT03977116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: These patients will receive placebo therapy after catheter ablation.
Trial: NCT03489317
Drug: Simvastatin 10mg
RxNorm normalized name: SIMVASTATIN 10MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants with elevated lipid levels will usually be prescribed simvastatin 10 mg at night. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
Trial: NCT01335165
Drug: ALXN1102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Ascending Dose IV
Trial: NCT01335165
Drug: ALXN1103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Ascending Dose IV or SC
Trial: NCT01925482
Drug: 6%CO2, 25%O2, balance N2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exposure of middle ear to gas
Trial: NCT01925482
Drug: 6% CO2, 0%O2, balance N2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exposure of middle ear to gas
Trial: NCT01925482
Drug: 20%CO2, 6%O2, balance N2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exposure of middle ear to gas
Trial: NCT01925482
Drug: 0%CO2, 6%O2, balance N2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exposure of middle ear to gas
Trial: NCT00568542
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 I.E. kg body weight placebo to erythropoetin beta
Trial: NCT01135615
Drug: calcium acetate
RxNorm normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: calcium acetate (1000 mg) 1 tablet three times a day
Trial: NCT01925482
Drug: 6% CO2, 6%O2, balance N2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exposure of middle ear to gas
Trial: NCT01925482
Drug: 6%CO2, 6%O2, 0%N2, balance argon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exposure of middle ear to gas
Trial: NCT02805439
Drug: S47445 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of S47445 50 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
Trial: NCT02805439
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of placebo taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
Trial: NCT02774291
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01392768
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, properly standardized to suit the characteristics of each dosage form (oral solution and tablets) of levetiracetam
Trial: NCT00537459
Drug: 16448
RxNorm normalized name: BARRIER,OSTOMY,NEW IMAGE H#16408
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01553591
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets twice daily
Trial: NCT03959345
Drug: Standard therapy group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adult patients with MSSA bacteraemia will be randomized to Standard therapy group: patients will receive intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
Trial: NCT03649139
Drug: Placebo drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sublingual placebo drops
Trial: NCT02768571
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo- saline 100 ml/day \* 21 days with rehabilitation
Trial: NCT03872232
Drug: Ezetimibe/Rosuvastatin
RxNorm normalized name: EZETIMIBE/ROSUVASTATIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 8weeks
Trial: NCT01464229
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01366599
Drug: HEC or MEC
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any HEC or MEC, including aprepitant
Trial: NCT04484870
Drug: oral Danshu capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danshu group oral Danshu capsule, 2 tablets per time, 3 times a day (0.45g/ tablets, Sichuan Jishengtang Pharmaceutical Co., Ltd.)
Trial: NCT00531882
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg once a day
Trial: NCT00531882
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 15-23 mg/kg twice daily, maximum 3200 mg/day
Trial: NCT01494350
Drug: WR 279,396 topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin that will be applied to each lesion once a day for 20 days and covered with a sterile gauze and tape dressing.
Trial: NCT01361646
Drug: LC350189
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Ascending Dose: 10, 25, 50, 100, 200, 400, 600mg Multifle Ascending Dose: 100, 200, 400, 600, 800mg
Trial: NCT00918177
Drug: AP09004
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00918177
Drug: Carbidopa/Levodopa, immediate release
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03018691
Drug: OPA-15406
RxNorm normalized name: O-PHTHALALDEHYDE 22 g in 4000 mL TOPICAL LIQUID [Safe OPA]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03018691
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03196986
Drug: mil60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then maintains at 7.5mg/kg
Trial: NCT01308086
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin 200mg/m2 IV in 2 hours, days 1 \& 2, q2w, for 12 cycles
Trial: NCT01308086
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 8 cycles
Trial: NCT01308086
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin 200mg/m2 IV in 2 hours, days 1 \& 2, q2w, for 6 cycles
Trial: NCT01308086
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 4 cycles
Trial: NCT03958058
Drug: Anti-borrelial antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beside symptomatic therapy, patients received oral doxycycline 100 mg (Doxy®) twice daily or ceftriaxone 2 g (Lendacin®) once daily for 14 days. Antibiotic therapy was left to the discretion of treating physicians. Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
Trial: NCT00900666
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 2 cc sterile normal saline: will be injected in 0.5 cc aliquots into 4 different injectate sites within the rectus femoris (with EMG guidance) of the involved limb.
Trial: NCT03769064
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potential subjects will be screened to determine their eligibility for the study within 28 days of the first dose in the Qualification Phase (i.e., Days -28 to -2). Eligible subjects will be admitted to the clinical site on Day -1 of the Qualification Phase (Part 1) and randomized on Day 1 to receive placebo and MPH (60 mg) in 1 of 2 sequences with a 48-hour washout between dose administrations (i.e., dose administration on Days 1 and 3).
Trial: NCT00541125
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00541125
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04307953
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo during 6 month RCT, AZD0530 thereafter
Trial: NCT02476890
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two tablets matching gefapixant 50 mg), administered orally as a single dose in treatment Period 1 or treatment Period 2
Trial: NCT01804842
Drug: Met DR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin delayed-release tablets
Trial: NCT03444506
Drug: Placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03444506
Drug: DYMISTA nasal spray
RxNorm normalized name: Dymista Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183610
Drug: [14C] BI 1356 as oral (p.o.) solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183610
Drug: [14C] BI 1356 solution for i.v. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03285490
Drug: KX2-391 Ointment 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 1% (250 mg single-use packets); Dosage form: Ointment; Route of administration: Topical
Trial: NCT03285490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: Ointment; Route of administration: Topical
Trial: NCT02728206
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100 mg FDC tablet administered orally once daily
Trial: NCT01633528
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg
Trial: NCT00288691
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02387450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with same presentation as the active drug
Trial: NCT01272232
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide placebo of either 3.0 mg or 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
Trial: NCT02218645
Drug: WE 941 OD tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04353128
Drug: Melatonin 2mg
RxNorm normalized name: Vicks ZzzQuil PURE Zzzs Melatonin 2mg Extended-Release Tablet
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mg of prolonged release melatonin tablets per os (P.O.) before bedtime for 12 weeks
Trial: NCT04353128
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identically looking placebo tablets P.O. before bedtime for 12 weeks
Trial: NCT00040443
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00980135
Drug: Hydrocortison cream
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Application over 29 days
Trial: NCT01137032
Drug: Pandel Cream 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A thin coat of cream will be applied and rubbed into the affected areas, as well as normal skin, twice daily for 21 days
Trial: NCT01594229
Drug: ABT-199
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-199 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
Trial: NCT02041481
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02041481
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02806869
Drug: Single dose of ibuprofen (800 mg tablet)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02652936
Drug: AF-130
RxNorm normalized name: Canesten AF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AF-130 oral capsules (50 mg) administered as a single dose or once daily for 7 days
Trial: NCT02652936
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AF-130 matching placebo capsule
Trial: NCT03745001
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral liquid administration daily
Trial: NCT00591162
Drug: Tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two courses of IV Tetracycline(10mg./kg./day for two days)separated by a two week interval.
Trial: NCT01789255
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00002963
Drug: aminolevulinic acid hydrochloride
RxNorm normalized name: Aminolevulinic Acid Hydrochloride
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01834638
Drug: ABT-126
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule(s)
Trial: NCT01687296
Drug: placebo inhalation solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4ml 0.9% saline nebulized twice daily
Trial: NCT01687296
Drug: placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo soluble tablet, oral ,once daily
Trial: NCT01969006
Drug: Marcaine ½%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02624440
Drug: Standard myeloma treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The choice of myeloma standard treatment is at the discretion of the treating investigator guided by the national Danish guidelines for treatment of multiple myeloma
Trial: NCT02624440
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: P.o. clarithromycin 250 mg twice daily
Trial: NCT03745404
Drug: Placebo Plaster
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02155504
Drug: ASP3700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02624440
Drug: Observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation without prophylactic antibiotic
Trial: NCT02155504
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02314286
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin is a hydrophilic statin, short treatment (hours to days) with this type of statin improved the outcome of patients during acute myocardial infarction, sepsis, contrast-induced nephropathy, hepatic ischemia/reperfusion injury, emphasizing its preferential pleiotropic effects. Currently, the FDA classiﬁes all statins as pregnancy category X and discourages their use during pregnancy due to higher abortion rate and teratogenicity that were observed in animals exposed to hydrophobic statins during pregnancy. Since the use of statins after delivery is allowed, the present study will aim to evaluate whether Rosuvastatin may accelerates preeclampsia resolution following delivery and potentially reduce postpartum preeclampsia complications.
Trial: NCT02314286
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01929512
Drug: HCP1201 750/20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750mg Metformin/20mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
Trial: NCT01929512
Drug: Rosuvastatin 20mg
RxNorm normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
Trial: NCT03275740
Drug: PF-06755347 intravenous healthy participant
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of PF-06755347 will be administered intravenously dose levels 1, 2, 3, 4, 5, and 6.
Trial: NCT00736606
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One single dose of 40mg
Trial: NCT03275740
Drug: Placebo intravenous healthy participant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT03275740
Drug: PF-06755347 subcutaneous healthy participant
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single doses of PF-06755347 will be administered subcutaneously at dose levels of SC1, SC2, SC3, SC4, and SC5.
Trial: NCT03275740
Drug: Placebo subcutaneous healthy participant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator
Trial: NCT03275740
Drug: PF-06755347 subcutaneous ITP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single doses of PF-06755347 will be administered subcutaneously at 2 dose levels tested in healthy participants
Trial: NCT01410513
Drug: SAR245409
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:capsule Route of administration: oral
Trial: NCT00736606
Drug: AZD9056 + simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AZD9056: 400 mg od, 8 days simvastatin: one single dose of 40 mg on day 7
Trial: NCT02498769
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00509470
Drug: telmisartan plus hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / telmisartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with telmisartan (40 mg/day) plus hydrochlorothiazide (12.5 mg/day): If blood pressure is not reach to lower than 140/90 mmHg, dose of telmisartan can be increased to 80 mg/day
Trial: NCT04648813
Drug: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered daily, 2 inhalations per dose for a total of 8 doses
Trial: NCT01129414
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: matching tablet~Route of administration: oral
Trial: NCT00238979
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01964417
Drug: Colonoscopy after bowel cleansing
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02519699
Drug: norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increase in mean arterial pressure using norepinephrine
Trial: NCT03744767
Drug: Spironolactone 50 MG
RxNorm normalized name: spironolactone 50 MG
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration of Spironolactone, 25mg daily for 1 week, then 50mg daily until visit Month 3, followed by 25mg daily from visit Month 3 to visit Month 4
Trial: NCT02486016
Drug: Duragesic reference fentanyl TDS
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25 µg/hour
Trial: NCT02486016
Drug: Apotex generic fentanyl TDS
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25 µg/hour
Trial: NCT02486016
Drug: Mylan generic fentanyl TDS
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25 µg/hour
Trial: NCT03667157
Drug: every week IVMP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 pulses of intravenous methylprednisolone (IVMP) in every week schedule (for the first 6 weeks 0.5g IVMP per week, for the next 6 weeks 0.25g IVMP per week; cumulative dose 4.5g) according to EUGOGO recommendations
Trial: NCT02509923
Drug: Z-215 10mg
RxNorm normalized name: zinc pyrithione 10 MG/ML [Theraplex Z]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Z-215 10mg, capsules
Trial: NCT02509923
Drug: Z-215 20mg
RxNorm normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Z-215 20mg, capsules
Trial: NCT01292187
Drug: Oral calcitonin at dinnertime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral calcitonin at dinnertime.
Trial: NCT01292187
Drug: Oral placebo at dinnertime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo at dinnertime.
Trial: NCT01292187
Drug: Oral calcitonin at bedtime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral calcitonin at bedtime